AGCO Corporation vs BioNTech SE - ADR — how do they compare? AGCO Corporation trades at $100.89 (market cap $7.10B), while BioNTech SE - ADR trades at $93.24 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 3.3× AGCO Corporation's market cap, and AGCO Corporation pays a 1.18% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| AGCO | BNTX | |
|---|---|---|
Market Cap | $7.10B | $23.31B |
Sector | Industrials | Health |
52-Week High | $140.49 | $119.34 |
52-Week Low | $100.14 | $83.89 |
Enterprise Value | $9.37B | $6.60B |
Dividend Yield | 1.18% | — |
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $101.58, up 0.7% today, but remains under pressure after a Q2 2026 earnings miss and lowered full-year guidance triggered an 11% sell-off in late July 2026. The stock shows bearish technical signals with support near $99 and resistance at $102. Fundamentally, 2025 revenue was $10.08B with a net income margin of 7.2%, but 2026 projections indicate softer profitability. Recent leadership changes and ongoing securities investigations add uncertainty, though the consensus price target of $124.63 suggests potential upside from current levels.
The outlook is cautious due to weaker agricultural demand and earnings volatility. Investment appeal hinges on execution of the PTx growth strategy and margin recovery, but risks include legal probes and cyclical industry headwinds. Analyst sentiment is mixed with 38% buy ratings, reflecting divided views on near-term recovery prospects.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Trailing returns across standard periods
Latest headlines on both assets
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →